The role of NAT2 gene polymorphism in aetiology of the most frequent neurodegenerative diseases with dementia

Neurologia i Neurochirurgia Polska

Volumn 41, Issue 5, 2007, Pages 388-394

  Gołab Janowska, Monika ^a   Honczarenko, Krystyna ^a   Gawrońska Szklarz, Barbara ^a   Potemkowski, Andrzej ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Indywidualna Specjalistyczna Praktyka Lekarska   (Poland)

Author keywords

Alzheimer's disease; Dementia; NAT2 polymorphism; Parkinson's disease

Indexed keywords

ACYLTRANSFERASE; LEVODOPA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ARYLAMINE N-ACETYLTRANSFERASE; CASE-CONTROL STUDIES; DEMENTIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NEURODEGENERATIVE DISEASES; PARKINSON DISEASE; POLYMORPHISM, GENETIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 36749068274     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Agundez J.A., Jimenez-Jimenez F.J., Luengo A., et al. Slow allotypic variants of the NAT2 gene and susceptibility to early-onset Parkinson's disease. Neurology 1998; 51: 1587-1592.
2. Bandmann O., Vaughan J., Holmans P.A., et al. Association of slow acetylator genotype for N-acetyltransferase 2 with familial Parkinson's disease. Lancet 1997; 350: 1136-1139.
3. Jankovic J., Tolosa E. Parkinson's disease and movement disorders. Williams & Wilkins, Baltimore 1998.
4. Ladero J.M., Barquero M.S., Coria F., et al. Acetylator polymorphism in Alzheimer's disease. Eur J Med 1993; 2: 281-283.
5. Nicholl D.J., Bennett P., Hiller L., et al. A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders. Neurology 1999; 53: 1415-1421.
6. Maraganore D.M., Farrer M.J., Hardy J.A., et al. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphism in Parkinson's disease. Mov Disord 2000; 15: 714-719.
7. Bandmann O., Vaughan J.R., Holmans P.A., et al. Detailed genotyping demonstrates association between the slow acetylator genotype for N-acetyltransferase 2 (NAT2) and familial Parkinson's disease. Mov Disord 2000; 15: 30-35.
8. Bandmann O., Vaughan J., Holmans P.A., et al. Toxins, genetics, and Parkinson's disease: the role of N-acetyltransferase 2. Adv Neurol 1999; 80: 199-204.
9. Harhangi B.S., Oostra B.A., Heutink P., et al. N-acetyltransferase-2 polymorphism in Parkinson's disease: the Rotterdam Study. J Neurol Neurosurg Psychiatry 1999; 67: 518-520.
10. Ray-Chaudhuri K., Smith C.A., Gough A.C., et al. Debrisoquine hydroxylase gene polymorphism in Parkinson's disease and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 1995; 58: 109.
11. Rocha L., Garcia C., de Mendonca A., et al. N-acetyltransferase 2 (NAT2) genotype and susceptibility of sporadic Alzheimer's disease. Pharmacogenetics 1999; 9: 9-15.
12. Rogaeva E.A. The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease. Neuromolecular Med 2002; 2: 1-10.
13. Tanzi R.E., Kovacs D.M., Kim T.V., et al. The gene defects responsible for familial Alzheimer's disease. Neurobiol Dis 1996; 3: 159-168.
14. Daniel S.E., Lees A.J. Parkinson's Disease Society Brain Bank, London: overview and research. J Neural Transm Suppl 1993; 39: 165-172.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (DSM-IV). American Psychological Association, Washington 1994.
16. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-Mental State". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
17. Morris J.C. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9: 173-176.
18. Reisberg B., Ferris S.H., de Leon M.J., et al. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry 1982; 139: 1136-1139.
19. Beck A.T., Steer R.A., Brown G.K. Manual for the Beck Depression Inventory 2nd ed. Psychological Corporation, San Antonio 1996.
20. Fahn S., Elton R.L. Unified Parkinson's Disease Rating Scale. In: Fahn S., Marsden C.D., Calne D.B., et al. [eds]. Recent Development in Parkinson's Disease. MacMillan 1987; pp. 153-164.
21. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
22. McKhann G., Drachman D., Folstein M., et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 939-944.
23. Hachinski VC., Iliff L.D., Zilhka E., et al. Cerebral blood flow in dementia. Arch Neurol 1975; 32: 632-637.
24. Smith C.A., Gough A.C., Leigh P.N., et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease. Lancet 1992; 339: 1375-1377.
25. Barbeau A., Cloutier T., Roy M., et al. Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine. Lancet 1985; 2: 1213-1216.
26. Kłodowska-Duda G.A., Opala G.M., Ochudlo S.G. Rola polimorfizmu N-acetylotransferazy 2 w patogenezie choroby Parkinsona. Neurol Neurochir Pol 2003; 37: 1095-1101.
27. Le Couter D.G., McLean A.J., Taylor M.C., et al. Pesticides and Parkinson's disease. Biomed Pharmacother 1999; 53: 122-130.
28. Cascorbi I., Drakoulis N., Brockmoller J., et al. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57: 581-592.
29. Lin L.H., Han C.Y., Lin B.K., et al. Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics 1994; 4: 125-134.
30. Gawrońska-Szklarz B. Molekularne podstawy polimorfizmu genów CYP2D6 i NAT2*. XIV Zimowa Szkoła Instytutu Farmakologii PAN, Mogilany 1997, pp. 51-58.
31. Nicholl D.J., Bennett P. Acetylator genotype and Parkinson's disease. Lancet 1998; 351: 141-142.
32. Białecka M., Gawrońska-Szklarz B., Droździk M., et al. N acetylotransferase 2 polymorphism in sporadic Parkinson's disease in a Polish population. Eur J Clin Pharmacol 2002; 57: 857-862.
33. Ladero J.M., Jimenez F.J., Benitez J., et al. Acetylator polymorphism in Parkinson's disease. Eur J Clin Pharmacol 1989; 37: 391-393.
34. Tan E.K., Khajavi M., Thornby J.I., et al. Variability and validity of polymorphism association studies in Parkinson's disease. Neurology 2000; 55: 533-538.